-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology qPCR Assay Platform
Author:
InnoModels
Release time:
2024-07-17
On the road of tumor drug development, accurate and efficient detection technology is crucial for the evaluation of drug effects, research on mechanism of action and safety assurance. InnoModels Biotechnology (Beijing) Co., Ltd. provides a one-stop efficient and precise solution for tumor drug discovery and development with its unique qPCR assay platform.
Platform Overview:
InnoModels Bio's qPCR platform, based on real-time quantitative polymerase chain reaction (qPCR) technology, is a highly sensitive and accurate nucleic acid detection method. The platform not only provides researchers with an accurate assessment of target gene expression and drug effects, but also demonstrates significant advantages in the drug development process.
Platform features:
1. Highly sensitive and precise: The qPCR platform is capable of detecting extremely low levels of target nucleic acids and providing accurate quantitative data. This feature enables researchers to more accurately assess the activity and effects of drugs, thus accelerating the drug development process.
2. Specialized design: The platform is specifically optimized for the characteristics of nucleic acid-coupled drugs and mRNA drugs to ensure efficient and specific detection. This makes the platform more relevant and useful in oncology drug discovery.
3. High throughput: The platform supports simultaneous detection of multiple samples, which greatly improves detection efficiency. Researchers can complete the testing of a large number of samples in a short period of time, further shortening the drug development cycle.
4. Flexibility: The platform can be customized according to different research needs to meet the diverse experimental needs of researchers. Whether it is gene expression analysis, drug effect evaluation or mechanism research, the platform can provide personalized solutions.

Applications in tumor drug development:
1. Drug effect assessment: By measuring the expression of target genes, researchers can accurately assess the activity and effect of drugs, providing powerful support for drug screening and optimization.
2. Mechanism study: In-depth understanding of the mechanism of action of nucleic acid-coupled drugs and mRNA drugs provides direction for drug optimization. The data provided by the platform can reveal the interaction relationship between drugs and targets, providing scientific basis for drug design.
3. Safety assessment: By detecting the expression of relevant marker genes, researchers can assess the potential toxicity and safety of drugs. This helps to identify and solve potential safety issues at the early stage of drug development and reduce the risk of drug development.
Cutting-edge technology and expert support:
InnoModels Bio's qPCR assay platform utilizes the latest qPCR technology to ensure that researchers get the best results. In addition, the company has an expert team of experienced scientists to provide researchers with strong technical support and one-stop services. From sample processing to data analysis, the company can provide researchers with all-round support.
In conclusion, InnoModels' qPCR assay platform demonstrates significant advantages in oncology drug discovery and development with its highly sensitive and precise, specialized design, high throughput and flexibility. The platform not only improves the efficiency and quality of drug discovery and development, but also provides researchers with more experimental options and data support. In the future, with the deepening and development of tumor drug R&D, the qPCR assay platform of InnoModels Biotechnology will continue to play an important role and contribute to tumor drug R&D.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd